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Abstract. dNA methylation is an important epigenetic 
modification that has been implicated in the pathogenesis 
of atherosclerosis. Although previous studies have identified 
various cpG sites and genes whose methylation is associated 
with atherosclerosis in populations with European or Mexican 
ancestry, the genome-wide pattern of dNA methylation in the 
atherosclerotic human aorta is yet to be elucidated in Japanese 
individuals. In the present study, a genome-wide analysis of 
dNA methylation at ~853,000 cpG sites was performed 
using 128 postmortem aortic intima specimens obtained from 
64 Japanese patients. To avoid the effects of interindividual 
variation, intraindividual paired comparisons were performed 
between atheromatous plaque lesions and corresponding 
plaque‑free tissue for each patient. Bisulfite‑modified genomic 
dNA was analyzed using a specific microarray for dNA 
methylation. dNA methylation at each cpG site was calcu-
lated as the β value, where β = (intensity of the methylated 
allele)/(intensity of the methylated allele + intensity of the 
unmethylated allele + 100). Bonferroni's correction for statis-
tical significance of association was applied to compensate 
for multiple comparisons. The methylation of 2,679 cpG 
sites differed significantly (P<5.86x10-8) between athero-
matous plaque lesions and the corresponding plaque-free 
intima, with 2,272 and 407 cpG sites in atheromatous 
plaques being hyper- or hypomethylated, respectively. A total 
of 5 hypermethylated cpG sites in atheromatous plaques 
were demonstrated to have a difference in β value of >0.15 
(plaque lesion-plaque-free intima) and 11 had a β ratio of >1.50 
(plaque/plaque-free intima). A further 15 and 17 hypomethyl-
ated cpG sites in atheromatous plaques were observed to have 
a difference in β value of <-0.15 or a β ratio of <0.67, respec-
tively. According to these limits, a total of 16 novel genes that 
were significantly hyper‑ or hypomethylated in atheromatous 
plaque lesions compared with the plaque-free intima were 
identified in the present study. The results of the present study 
suggest that the methylation of these genes may contribute to 
the pathogenesis of atherosclerosis in the Japanese population.
Introduction
Atherosclerosis is a chronic inflammatory vascular disease 
characterized by infiltration of lipid particles into the arterial 
wall, leading to inflammatory responses accompanied by 
endothelial cell dysfunction and recruitment of inflamma-
tory and immune cells (1). Previous studies have reported 
that epigenetic mechanisms may be associated with the 
pathogenesis of atherosclerosis and may account for some 
of the missing heritability in atherosclerotic cardiovascular 
disease (2,3). Epigenetic control of transcription results in 
a heritable change in gene expression without a change in 
dNA sequence. dNA methylation and post-translational 
modifications of histone tails, including lysine methylation 
and acetylation, are the most common mechanisms that cause 
changes in dNA accessibility (3).
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DNA methylation is a vital epigenetic modification that has 
been implicated in the pathogenesis of a number of common 
complex diseases, including atherosclerosis and cardiovascular 
disease (4-12). dNA methylation serves a role in a variety of 
cellular processes (5,13), is affected by environmental factors 
and is influenced by age, sex and genetic variants (4,6). As 
such, elucidating the differences in dNA methylation patterns 
between atherosclerotic plaque lesions and plaque-free intima 
tissue may provide an insight into the underlying molecular 
mechanisms of atherosclerotic cardiovascular disease. 
Although previous analyses of dNA methylation have identi-
fied various CpG sites and genes associated with atherosclerosis 
in European-ancestry (14-17) or Mexican (18) populations, the 
pattern of dNA methylation in the atherosclerotic human aorta 
at the genome-wide level has remained relatively uncharacter-
ized in Japanese individuals.
A previous study examined dNA methylation at 
~450,000 cpG sites (human Methylation 450 Beadchip; 
Illumina, Inc., san diego, cA, UsA) in 48 human aortic intima 
specimens obtained from 24 autopsy cases (19); it was demon-
strated that DNA methylation was significantly (P<1.03x10-7) 
increased at 30 cpG sites and reduced at 15 cpG sites in ather-
omatous plaque tissues compared with plaque-free intima (19). 
In the present study, to further assess the association between 
dNA methylation and the development of atherosclerosis, a 
genome-wide analysis of dNA methylation at ~853,000 cpG 
sites (Infinium MethylationEPIC BeadChip) was performed in 
128 human aortic intima specimens obtained from 64 autopsy 
cases. compared with the human Methylation 450 Beadchip 
array, the newly developed Infinium MethylationEPIc 
Beadchip array is a more reliable tool for comprehensive 
DNA methylation analyses (20). A total of 16 significantly 
hyper- or hypomethylated novel genes in atheromatous plaque 
lesions were identified.
Materials and methods
Study specimens. characteristics of the 64 deceased patients 
from whom tissues were harvested for use in the present 
study are presented in Table I. Inter-individual variation in 
dNA methylation was detected for the same cell and tissue 
type of unrelated individuals (21,22). To avoid the effects of 
such variation, intra-individual paired comparisons of dNA 
methylation were performed between atheromatous plaque 
lesions and corresponding plaque-free intima. A total of 
128 postmortem specimens of the aortic intima were obtained 
from 64 deceased Japanese patients for analysis. The speci-
mens were collected specifically for this study in participating 
hospitals (Gifu Prefectural Tajimi hospital, Tajimi; Japanese 
Red cross Nagoya First hospital, Nagoya; kasugai Municipal 
hospital, kasugai; Tokyo Metropolitan Geriatric hospital, 
Tokyo, Japan) between August 2012 and August 2017. A total 
of 48 of these specimens obtained from 24 subjects were also 
analyzed in a previous study (19).
Immunohistochemical analysis of atheromatous plaque lesions 
and plaque‑free intima. specimens of atheromatous plaque 
lesions and plaque-free intima were subjected to immunohis-
tochemical analysis as described previously (19). Formalin 
(20%)‑fixed (6 h at room temperature) and paraffin‑embedded 
Table I. Patient characteristics (n=64).
characteristic Value
Mean age (years) ± sd (range) 75.8±12.9 (41-95)
sex (male/female, %) 73.4/26.6
Mean body mass index (kg/m2) ± sd 19.8±4.3 (12.2-32.2)
(range)
current or former smoker (%) 57.5
hypertension (%) 40.6
diabetes mellitus (%) 20.3
dyslipidemia (%) 9.4
chronic kidney disease (%) 32.8
Myocardial infarction (%) 21.9
Ischemic stroke (%) 9.4
cause of death (n)
  Pneumonia 13
  Myocardial infarction 12
  dissecting aortic aneurysm 4
  Amyloidosis 2
  dilated cardiomyopathy 2
  hypertrophic cardiomyopathy 2
  Interstitial pneumonia 2
  Lung cancer 2
  Necrotizing enterocolitis 2
  Amyotrophic lateral sclerosis 1
  Arrhythmogenic right ventricular 1
  cardiomyopathy
  Aspergillosis 1
  Bacterial meningitis 1
  cardiac sarcoidosis 1
  chronic obstructive pulmonary disease 1
  Embolic stroke 1
  Gastric cancer 1
  heatstroke 1
  huntingdon's disease 1
  Intestinal obstruction 1
  Ischemic heart disease 1
  Malignant mesothelioma 1
  Malnutrition 1
  Multiple myeloma 1
  Parkinson's disease 1
  Primary biliary cirrhosis 1
  Pulmonary hypertension 1
  Relapsing polychondritis 1
  Renal failure 1
  superior mesenteric artery 1
  thrombosis
  Traumatic lung contusion 1
  Valvular heart disease 1
sd, standard deviation.
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  41:  2724-2732,  20182726
sections (3 µm) were deparaffinized, hydrated, immersed in 
0.01 mol/l citrate buffer (ph 6.0), and heated for 10 min in a 
pressure cooker. Endogenous peroxidase was blocked with 3% 
hydrogen peroxide for 5 min at room temperature and sections 
were incubated for 30 min at room temperature with mouse 
monoclonal antibodies against human α-smooth muscle actin 
(1:100; M0851; dako; Agilent Technologies, Inc., santa clara, 
cA, UsA), cd68 (1:100; N1576; dako; Agilent Technologies, 
Inc.) and cd45 (1:100; 722071; Nichirei Bioscience, Inc., 
Tokyo, Japan). Proteinase k (0.1%) pre-treatment (5 min at 
room temperature) was used for cd68 and cd45. sections 
were subsequently incubated for 30 min at room temperature 
with horseradish peroxidase (hRP)-conjugated goat poly-
clonal antibody to rabbit and mouse immunoglobulin (1:100; 
k5007; dako; Agilent Technologies, Inc.). sections were 
stained with diaminobenzidine for 10 min at room tempera-
ture (chemMate Envision/hRP kit; k5007; dako; Agilent 
Technologies, Inc.).
The present study was approved by the committees on 
the Ethics of human Research of: Mie University Graduate 
school of Medicine, Tsu; Tokyo Metropolitan Institute 
of Gerontology, Tokyo; Japanese Red cross Nagoya First 
hospital, Nagoya; Gifu Prefectural Tajimi hospital, Tajimi; 
and kasugai Municipal hospital, kasugai (all Japan). written 
informed consent was obtained from the families of the 
deceased patients.
Genome‑wide analysis of DNA methylation. The intima tissue 
samples were frozen at ‑80˚C immediately following dissec-
tion from the aorta. The finely minced (cut to ~1 mm3 with 
a surgical blade) tissue was subsequently mixed with 250 µl 
phenol-chloroform and centrifuged at 12,000 x g for 5 min at 
room temperature. The upper aqueous phase was collected for 
the precipitation of genomic dNA and 100% ethanol containing 
0.3 mol/l sodium acetate was added and incubated at ‑30˚C for 
30 min. The mixture was then centrifuged at 12,000 x g for 
20 min at 4˚C and the DNA pellet was dissolved in Tris‑EDTA 
buffer (pH 7.4; Takara Bio, Inc., Otsu, Japan). Bisulfite conver-
sion of genomic dNA was performed using an EZ dNA 
Methylation kit (Zymo Research corp., Irvine, cA, UsA).
The bisulfite‑modified genomic DNA was analyzed for 
DNA methylation with a DNA methylation‑specific micro-
array (Infinium MethylationEPIC BeadChip, Illumina, Inc.) 
that included 853,307 cpG sitets distributed throughout 
the entire genome. A total of 439,562 (91.1%) of these sites 
were assessed in a previous study (19) using the human 
Methylation 450 Beadchip. Furthermore, 413,745 additional 
cpG sites, including 333,265 located in enhancer regions, 
were identified by the Encyclopedia of DNA elements (23) 
and FANTOM5 (24) projects. The Infinium Methylation 
EPIc Beadchip microarray also interrogates 2,880 cNG 
(c, cytosine; N, any nucleotide; G, guanine) sites (20).
Methylation at cpG sites in genomic dNA isolated from 
atheromatous plaque lesions or plaque-free intima was assessed 
using a Genomestudio Methylation Module (Illumina, Inc.). 
call rate values for the 128 specimens were all >99.3%, with a 
mean value of 99.7%. The dNA methylation level at each cpG 
site was calculated as the β value, where β = (intensity of the 
methylated allele)/(intensity of the methylated allele + intensity 
of the unmethylated allele + 100) (25).
Statistical analysis. The levels of dNA methylation at 853,307 
cpG sites (β values) were compared between atheromatous 
plaque lesions and plaque-free intima using the unpaired 
student's t-test. To compensate for multiple comparisons, 
Bonferroni's correction for the statistical significance of asso-
ciations was used. The significance level was thus P<5.86x10-8 
(0.05/853,307) for the genome-wide analysis of dNA methyla-
tion. statistical tests were performed using JMP Genomics 6.0 
software (sAs Institute, Inc., cary, Nc, UsA).
Analysis of public databases. The potential association 
between CpG sites and genes identified in the present study 
with atherosclerosis was assessed by searching public data-
bases between January 2007 and October 2017 [Google 
scholar (http://scholar.google.co.jp); PubMed (National 
center for Biotechnology Information, Bethesda, Md, UsA; 
https://www.ncbi.nlm.nih.gov/pubmed), GwAs catalog 
(National human Genome Research Institute, Bethesda, Md, 
UsA and European Bioinformatics Institute, hinxton, Uk; 
http://www.ebi.ac.uk/gwas) and GwAs central (http://www.
gwascentral.org)] for previously associated phenotypes. 
Genome-wide analyses of dNA methylation or genome-wide 
association studies for atherosclerosis or cardiovascular disease 
were included in the results. dNA methylation analyses or 
association studies of candidate genes were excluded.
Results
Study specimens. In the present study, the methylation status of 
853,307 CpG sites of genomic DNA purified from atheroma-
tous plaque lesions and corresponding plaque-free intima were 
compared. Manhattan and volcano plots for the genome-wide 
analysis of differences in methylation status at these sites are 
presented in Figs. 1 and 2, respectively. Following Bonferroni's 
correction, the methylation of 2,679 cpG sites was revealed 
to differ significantly (P<5.86x10-8) between atheromatous 
plaque lesions and corresponding plaque-free intima. The 
50 CpG sites with the lowest P‑values (P≤3.48x10-12) are 
presented in Table II; to the best of our knowledge, none of 
these sites have previously been reported to be associated with 
atherosclerosis.
Genome‑wide analysis of gene methylation. Of the 2,679 cpG 
sites significantly associated with atherosclerosis, 2,272 and 
407 sites were hyper- or hypomethylated, respectively, in 
atheromatous plaque lesions compared with plaque-free 
intima. Among the 2,272 cpG sites that were hypermethyl-
ated in atheromatous plaque lesions, 5 had a β value difference 
(plaque lesion-plaque-free intima) >0.15 (Table III) and 11 had 
a β ratio (plaque lesion/plaque-free intima) >1.50 (Table IV). 
Among these cpG sites, cg15648389 of homeobox (HOX) 
C4 (15), cg17466857 of HOXA11-HOXA11‑AS (14,15), 
cg15700739 of HOXC4/HOXC5 (17) and cg02384661 of 
HOXC11 (15) have previously been demonstrated to be associ-
ated with atherosclerosis.
Among the 407 cpG sites hypomethylated in atheromatous 
plaque lesions, 15 were observed to have a β value difference 
<-0.15 (Table V) and 17 sites had a β ratio <0.67 (Table VI). Of 
these cpG sites, cg03217995 of HOXA9 (15) was previously 
reported to be associated with atherosclerosis.
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Table II. A total of 50 CpG sites with the lowest P‑values (P≤3.48x10-12) for the comparison of methylation status (β values) 
between atheromatous plaque lesions and plaque-free intima by a genome-wide analysis of dNA methylation.
 chromosome:  Methylation Mean β value Mean β value β ratio (plaque/
cpG position Gene site (plaque) (plaque-free) plaque-free) P-value
cg06792393 5:139242953 NRG2 Body 0.7906 0.6985 1.13 1.11x10-16
cg19517104 7:134204895   0.8458 0.7535 1.12 5.60x10-15
cg02580923 12:117470541   0.4173 0.5093 0.82 9.21x10-15
cg15374435 13:80911692 SPRY2 Body 0.7301 0.5885 1.24 1.42x10-14
cg15796536 5:140873082 PCDHGA8 Body 0.8437 0.7766 1.09 1.82x10-14
cg06827792 7:36723794 AOAH Body 0.8015 0.7180 1.12 1.92x10-14
cg06996940 15:28197405 OCA2 Body 0.8065 0.7492 1.08 3.82x10-14
cg25506501 3:59521337   0.7693 0.6500 1.18 5.56x10-14
cg22055728 7:27205658 HOXA9 Tss1500 0.1162 0.2026 0.57 7.80x10-14
cg15542608 6:12827379 PHACTR1 Body 0.8312 0.7371 1.13 7.86x10-14
cg07145664 6:2579591   0.6933 0.5966 1.16 1.21x10-13
cg26968433 12:76397292   0.7965 0.7363 1.08 1.28x10-13
cg24082440 21:33672186 MRAP Body 0.8245 0.7598 1.09 1.53x10-13
cg27554156 12:13248725 GSG1 Body, Tss200 0.8345 0.7781 1.07 1.64x10-13
cg12433228 2:177486421   0.6642 0.5898 1.13 1.83x10-13
cg12336358 1:114000078 MAGI3 Body 0.7586 0.6597 1.15 2.34x10-13
cg09723384 9:122217063   0.5751 0.6710 0.86 2.89x10-13
cg05454595 5:139243335 NRG2 Body 0.6737 0.5909 1.14 5.69x10-13
cg06019613 2:18717524   0.4711 0.6044 0.78 7.60x10-13
cg22651416 8:10643634 PINX1 Body 0.8567 0.7935 1.08 8.42x10-13
cg17882587 2:18933408   0.6727 0.5779 1.16 8.56x10-13
cg19691778 8:97157756 GDF6 Body 0.3900 0.5395 0.72 9.03x10-13
cg17820365 8:97157856 GDF6 Body 0.2811 0.4348 0.65 9.07x10-13
cg15086256 2:222631916   0.7039 0.6146 1.15 9.39x10-13
cg18141318 13:96350690 DNAJC3 Body 0.8180 0.7723 1.06 9.67x10-13
cg01754709 16:84961336   0.7191 0.6133 1.17 9.74x10-13
cg17128320 4:78633646   0.8804 0.8235 1.07 1.14x10-12
cg16597993 19:16578633 EPS15L1 Body 0.8226 0.7540 1.09 1.20x10-12
cg10224937 7:27208594 HOXA10‑AS,  Body 0.5089 0.6669 0.76 1.32x10-12
  HOXA10,
  HOXA9
cg12786452 17:62309293 TEX2 5'UTR 0.8392 0.7737 1.08 1.44x10-12
cg05069228 3:61793623 PTPRG Body 0.7403 0.6545 1.13 1.48x10-12
cg17741799 8:885656   0.7770 0.7158 1.09 1.49x10-12
cg23854860 7:27208590 HOXA10‑AS,  Body 0.5480 0.6949 0.79 1.67x10-12
  HOXA10,
  HOXA9
cg03735712 15:35263065 AQR Tss1500 0.7572 0.6263 1.21 1.69x10-12
cg09164580 8:97157878 GDF6 Body 0.4534 0.6044 0.75 1.73x10-12
cg10166915 14:54260975   0.7714 0.6711 1.15 1.73x10-12
cg17868595 3:90112204   0.7352 0.8183 0.90 1.74x10-12
cg00246590 12:126968300   0.8422 0.6984 1.21 1.84x10-12
cg19183743 7:27188020 HOXA6 Tss1500 0.3144 0.4401 0.71 1.86x10-12
cg27584713 6:12717016 PHACTR1 Tss1500 0.6815 0.5733 1.19 1.98x10-12
cg02750391 11:14274978 SPON1 Body 0.7800 0.7205 1.08 2.04x10-12
cg21310745 7:27208454 HOXA10‑AS,  Tss200, body 0.6244 0.7815 0.80 2.22x10-12
  HOXA10,
  HOXA9
cg16739092 20:17519424 BFSP1 Body, 5'UTR 0.3781 0.4932 0.77 2.23x10-12
cg03804397 11:76925617 MYO7A Body 0.7302 0.6427 1.14 2.31x10-12
cg22790931 7:39017455 POU6F2 Tss200 0.9070 0.8683 1.04 2.36x10-12
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Discussion
Atherosclerosis occurs as a result of endothelial damage and 
dysfunction that leads to the accumulation and oxidation of 
low-density lipoprotein (LdL) cholesterol in the vessel wall. 
Monocytes migrate from blood into the subendothelial intima 
and transform into macrophages, which accumulate lipids as 
foam cells in the lipid core of the atherosclerotic plaque (26,27). 
Inflammatory and thrombotic processes serve primary roles 
in the formation of atherosclerotic lesions and subsequent 
plaque rupture that causes acute coronary syndrome (26,27). 
A number of mechanisms by which changes in dNA methyla-
tion may affect the development of atherosclerosis have been 
identified. These mechanisms include the promotion of inflam-
mation, endothelial dysfunction, proliferation and migration of 
smooth muscle cells or monocyte-macrophages, extracellular 
matrix production, homocysteine metabolism and apoptosis of 
vascular cells (12,28,29). however, given the dynamic nature 
and tissue heterogeneity of atherosclerosis, defining the precise 
role of dNA methylation in the pathogenesis of this condition 
is challenging (12). A marked increase in dNA methylation 
in atherosclerotic lesions may warrant the development of 
dNA demethylation agents, including dNA methyltransferase 
Figure 1. Manhattan plot of P-values in the genome-wide analysis of cpG site methylation differences between atheromatous plaque and plaque-free intima. 
P-values (y-axis) are plotted as-log10(P) with respect to the physical chromosomal positions of the corresponding cpG sites (x-axis). The 10 cpG sites with the 
lowest P-values are indicated.
Figure 2. Volcano plot for the genome-wide analysis of differences in cpG 
site methylation between atheromatous plaques and plaque-free intimas. The 
x- and y-axes represent the difference in β values and P-values as-log10(P), 
respectively. The right and left halves of the plot correspond to hyper- or 
hypomethylation, respectively, in atheromatous plaque lesions compared 
with plaque‑free intima. The significance threshold is indicated by the hori-
zontal line. The cpG site cg26809635, which was hypermethylated in plaque 
lesions, had the largest difference in β value (0.1834) and the largest β ratio 
(3.20) and is indicated on the plot. The cpG sites hypomethylated in plaque 
lesions with the largest difference in β values (-0.1799, cg18461866) or the 
smallest β ratio (0.57, cg22055728) are also marked presented.
Table II. continued.
 chromosome:  Methylation Mean β value Mean β value β ratio (plaque/
cpG position Gene site (plaque) (plaque-free) plaque-free) P-value
cg23080761 12:111857575 SH2B3 Body 0.8194 0.7611 1.08 3.04x10-12
cg13913011 9:132711808 FNBP1 Body 0.7628 0.6517 1.17 3.18x10-12
cg08272913 18:68079266   0.6156 0.4664 1.32 3.33x10-12
cg20337028 17:75181836 SEC14L1 Body, 5'UTR 0.7624 0.6871 1.11 3.44x10-12
cg12873661 1:166277235   0.6713 0.5187 1.29 3.48x10-12
Tss1500 (200), within 1,500 (200) bp from the transcription start site; P<5.86x10-8 was considered statistically significant. NRG2, neureg-
ulin 2; sPRY2, sprout RTk signaling antagonist 2; PcdhGA8, protocadherin gamma subfamily A8; AOAh, acyloxyacyl hydrolase; OcA2, 
oculocutaneous albinism type 2; hOXA9, homeobox A9; PhAcTR1, phosphatase actin regulator 1; MRAP, melanocortin 2 receptor acces-
sory protein; GsG1, germ cell associated 1; MAGI3, membrane associated guanylate kinase, ww and Pd2 domains-containing 3; PINX1, 
PIN2/TERF1 interacting telomerase inhibitor 1; GdF6, growth differentiation factor 6; dNAJc3, dnaJ heat shock protein family member c3; 
EPs1sL1, epidermal growth factor receptor pathway substrate 13-like; As, antisense RNA; TEX2, testis expressed 2; PTPRG, protein tyro-
sine phosphatase receptor type G; AQR, Aquarius intron‑binding splceosomal factor; SPON1, spondin 1; BFSP1, beaded filament structural 
protein 1; MYO7A, myosin VIIa; sh2B3, sh2B adaptor protein 3; FNBP1, formin binding protein 1; sEc14L1, sEc14-like lipid binding 1; 
Tss, transcription start site; UTR, untranslated region.
YAMAdA et al:  EPIGENOME-wIdE AssOcIATION sTUdY OF AThEROscLEROsIs 2729
inhibitors, for the treatment of atherosclerotic cardiovascular 
disease (29).
Arteriosclerosis is classified into three types: athero- 
sclerosis, Mönckeberg medial sclerosis and arterioloscle-
rosis (30). Given that atherosclerosis is the most important 
pathological change in the development of cardiovascular 
disease (1,26,27,30), the aortic intima was examined in the 
present study. The results revealed that 2,272 and 407 cpG 
sites were hyper- and hypomethylated, respectively, in genomic 
dNA isolated from atheromatous plaque lesions compared 
with matched plaque-free intima. A total of 5 cpG sites had a 
>0.15 difference in β values and 11 cpG sites had a β ratio of 
>1.50. Among these cpG sites, cg15648389 of HOXC4 (15), 
cg17466857 of HOXA11-HOXA11‑AS (14,15), cg15700739 of 
HOXC4/HOXC5 (17) and cg02384661 of HOXC11 (15) have 
previously been reported to be associated with atherosclerosis. 
A total of 10 novel cpG sites (cg26809635, cg23786812, 
cg27178293, cg12873661, cg18040901, cg00576279, 
cg08857479, cg00862376, cg00187380, cg05951084) that 
were significantly hypermethylated in atheromatous plaque 
lesions compared with plaque-free intima were identified 
in the present study. Of these 10 cpG sites, cg18040901 is 
located in the HOX transcript antisense RNA (HOTAIR) gene, 
whose methylation status has not previously been associated 
with atherosclerosis. The HOTAIR gene is located at chromo-
some 12q13.13 and encodes a protein that has been reported 
to promote the proliferation and migration of vascular 
endothelial cells and to protect these cells against oxidized 
LdL-induced injury and apoptosis (31). Endothelial damage 
and dysfunction are early key processes in the development of 
atherosclerosis, resulting in the accumulation and oxidation of 
LdL-cholesterol in the arterial wall (26,27), and so HOTAIR 
may protect against this (31).
A total of 15 cpG sites with a <-0.15 difference in β values 
and 17 cpG sites with a β ratio of <0.67 were identified 
in the present study, including 2 cpG sites (cg13669152, 
Table IV. Eleven CpG sites whose methylation status differed significantly (P<5.86x10-8) between atheromatous plaque lesions 
and plaque-free intima with a β ratio (plaque/plaque-free) of >1.50.
 chromosome:  Methylation Mean β value Mean β value β ratio (plaque/
cpG position Gene site (plaque) (plaque-free) plaque-free) P-value
cg26809635 12:54355087   0.2669 0.0835 3.20 6.35x10-10
cg18040901 12:54357530 HOTAIR Body 0.1839 0.0979 1.88 6.12x10-11
cg00576279 12:54427293 HOXC4, HOXC5 5'UTR, body 0.2516 0.1419 1.77 5.04x10-9
cg17466857 7:27225528 HOXA11‑AS,  Body, Tss1500 0.2618 0.1479 1.77 1.16x10-8
  HOXA11
cg08857479 12:54369987 HOXC11 3'UTR 0.3479 0.2112 1.65 1.93x10-8
cg27178293 12:54371246   0.4042 0.2484 1.63 1.24x10-8
cg15700739 12:54427700 HOXC4, HOXC5 5'UTR, body 0.3313 0.2050 1.62 1.15x10-9
cg00862376 12:54343711   0.2745 0.1708 1.61 5.27x10-9
cg00187380 12:54427384 HOXC4, HOXC5 5'UTR, body 0.3373 0.2144 1.57 2.21x10-8
cg02384661 12:54369638 HOXC11 3'UTR 0.3804 0.2450 1.55 5.36x10-9
cg05951084 12:54343681   0.3480 0.2304 1.51 7.64x10-9
Tss1500, within 1,500 bp from the transcription start site. hOTAIR, hOX transcript antisense RNA; hOX, homeobox; -As, antisense RNA; 
UTR, untranslated region; Tss, transcription start site.
Table III. Five CpG sites whose methylation status differed significantly (P<5.86x10-8) between atheromatous plaque lesions and 
plaque-free intima with a difference in β values (plaque lesion-plaque-free intima) of >0.15.
 chromosome:   Mean β value Mean β value β ratio (plaque/ difference in β values
cpG position Gene (plaque) (plaque-free) plaque-free) (plaque-plaque-free) P-value
cg26809635 12:54355087  0.2669 0.0835 3.1957 0.1834 6.35x10-10
cg23786812 7:156296516  0.5526 0.3922 1.4090 0.1604 4.12x10-12
cg15648389 12:54448769 HOXC4 0.5564 0.4005 1.3893 0.1559 3.60x10-11
cg27178293 12:54371246  0.4042 0.2484 1.6270 0.1558 1.24x10-8
cg12873661 1:166277235  0.6713 0.5187 1.2941 0.1526 3.48x10-12
hOXc4, homeobox c4.
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Table V. Fifteen CpG sites whose methylation status differed significantly (P<5.86x10-8) between atheromatous plaque lesions 
and plaque-free intima with a difference in β values (plaque lesion-plaque-free intima) of <-0.15.
     β ratio difference in 
 chromosome:  Mean β value Mean β value (plaque/ β values P-value
cpG position Gene (plaque) (plaque-free) plaque-free) (plaque-plaque-free) 
cg18461866 3:59996864 FHIT 0.3759 0.5558 0.6763 -0.1799 1.78x10-10
cg21007852 7:27203546 HOXA9 0.5134 0.6904 0.7435 -0.1771 2.96x10-11
cg25227803 10:102239027 WNT8B 0.3980 0.5727 0.6951 -0.1746 1.84x10-11
cg03217995 7:27203430 HOXA9 0.5377 0.7107 0.7565 -0.1731 5.49x10-10
cg02886033 7:27208114  0.5367 0.7048 0.7615 -0.1681 7.82x10-10
cg11052578 21:39695801  0.3391 0.5064 0.6697 -0.1672 4.05x10-8
cg13669152 6:130923610  0.4987 0.6580 0.7579 -0.1593 2.46x10-8
cg10224937 7:27208594 HOXA10‑AS,  0.5089 0.6669 0.7631 -0.1580 1.32x10-12
  HOXA10, HOXA9
cg09699744 12:54390705 HOXC‑AS2 0.3719 0.5298 0.7020 -0.1579 1.60x10-10
cg21310745 7:27208454 HOXA10‑AS, 0.6244 0.7815 0.7990 -0.1571 2.22x10-12
  HOXA10, HOXA9
cg01016793 15:64894722 ZNF609 0.4212 0.5773 0.7297 -0.1561 1.03x10-11
cg10374314 7:27189610 HOXA‑AS3 0.5017 0.6558 0.7650 -0.1541 4.03x10-11
cg17820365 8:97157856 GDF6 0.2811 0.4348 0.6465 -0.1537 9.07x10-13
cg09164580 8:97157878 GDF6 0.4534 0.6044 0.7502 -0.1510 1.73x10-12
cg06136628 7:35289993 TBX20 0.2790 0.4293 0.6498 -0.1503 4.81x10-10
FHIT, fragile histidine triad; HOX, homeobox; WNT8B, wnt family member 8B; ‑AS, antisense RNA; ZNF609, zinc finger protein 609; 
GdF6, growth differentiation factor 6; TBX20, T-box 20.
Table VI. Seventeen CpG sites whose methylation status differed significantly (P<5.86x10-8) between atheromatous plaque 
lesions and plaque-free intima with a β ratio (plaque/plaque-free) of <0.67.
 chromosome:   Methylation Mean β value Mean β value β ratio
cpG position Gene site (plaque) (plaque-free) (plaque/plaque-free) P-value
cg22055728 7:27205658 HOXA9 Tss1500 0.1162 0.2026 0.57 7.80x10-14
cg13335081 8:66894111   0.1758 0.2913 0.60 1.67x10-8
cg23345300 2:177000621   0.1669 0.2752 0.61 3.81x10-8
cg04122553 14:21250646   0.1587 0.2615 0.61 3.43x10-9
cg24719020 7:27187943 HOXA6 Tss1500 0.2018 0.3324 0.61 1.51x10-9
cg14554869 5:74231171   0.1656 0.2630 0.63 9.29x10-11
cg11348442 2:220117784 TUBA4B,  Tss200, body 0.1177 0.1869 0.63 5.22x10-8
  TUBA4A     
cg10893095 6:85478296   0.2545 0.4008 0.64 1.10x10-10
cg26437522 7:27174169   0.2220 0.3460 0.64 4.59x10-9
cg01428378 12:123259789 CCDC62 Body 0.1784 0.2770 0.64 2.67x10-8
cg17820365 8:97157856 GDF6 Body 0.2811 0.4348 0.65 9.07x10-13
cg25541958 8:1992965 MYOM2 Tss200 0.1679 0.2585 0.65 4.63x10-11
cg06136628 7:35289993 TBX20 Body 0.2790 0.4293 0.65 4.81x10-10
cg19783626 7:98311436   0.2204 0.3366 0.65 3.72x10-12
cg00980698 14:21250509 RNASE6 3'UTR 0.1554 0.2365 0.66 1.67x10-10
cg12110087 7:27187691 HOXA6 Tss1500 0.2103 0.3168 0.66 8.08x10-9
cg11052578 21:39695801   0.3391 0.5064 0.66 4.05x10-8
Tss1500 (200), within 1,500 (200) bp from the transcription start site. hOX, homeobox; TUBA4B/4A, tubulin alpha 4a and 4b; ccdc62, 
coiled-coil domain containing 62; GdF6, growth differentiation factor 6; MYOM2, myomesin 2; TBX2-, T-box 20; RNAsE6, ribonuclease A 
family member k6; Tss, transcription start site; UTR, untranslated region.
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cg13335081) located in enhancer regions as described by 
the FANTOM5 project (24). Of these sites, cg03217995 
of HOXA9 (15) was previously reported to be associated 
with atherosclerosis. Additionally, 28 novel cpG sites that 
were significantly hypomethylated in atheromatous plaque 
lesions compared with plaque-free intima were identified 
in the present study: cg18461866, cg21007852, cg25227803, 
cg02886033, cg11052578, cg13669152, cg10224937, 
cg09699744, cg21310745, cg01016793, cg10374314, 
cg17820365, cg09164580, cg06136628, cg22055728, 
cg13335081, cg23345300, cg04122553, cg24719020, 
cg14554869, cg11348442, cg10893095, cg26437522, 
cg01428378, cg25541958, cg19783626, cg00980698 and 
cg12110087. Of these sites, 16 are located in genes whose 
methylation status has not previously been reported as 
associated with atherosclerosis, including fragile histidine 
triad (FHIT; cg18461866), wnt family member 8B (WNT8B; 
cg25227803), HOXA10-HOXA10‑antisense RNA (AS; 
cg10224937 and cg21310745), HOXC cluster antisense RNA 2 
(HOXC‑AS2; cg09699744), zinc finger protein 609 (ZNF609; 
cg01016793), HOXA‑AS3 (cg10374314), growth differentiation 
factor 6 (GDF6; cg17820365, cg09164580), T‑box 20 (TBX20; 
cg06136628), HOXA6 (cg24719020, cg12110087), tubulin 
alpha 4a and 4b (TUBA4A/TUBA4B; cg11348442), coiled‑coil 
domain containing 62 (CCDC62; cg01428378), myomesin 2 
(MYOM2; cg25541958) and ribonuclease A family member k6 
(RNASE6; cg00980698).
TBX20 is located at chromosome 7p14.2 and encodes a 
protein that has been demonstrated to protect endothelial 
cells against oxidized LdL-induced injury via upregulating 
peroxisome proliferator-activated receptor γ, indicating that it 
may protect against the development of atherosclerosis (32). 
It has also previously been determined that a polymorphism 
(rs3206736) near TBX20 is associated with a decrease in 
diastolic blood pressure (33). several of the genes that were 
demonstrated to be hypomethylated in atherosclerotic tissues 
in the present study have been reported to be correlated with 
atherosclerosis-related phenotypes: The FHIT gene located at 
chromosome 3p14.2 is associated with body mass index (34); 
the HOXA10-HOXA10‑AS gene at 7p15.2 is expressed 
differentially in porcine coronary and iliac artery endothelial 
cells (35); the HOXA‑AS3 gene at 7p15.2 is associated with 
chronic venous disease (36) and monocyte count (37); HOXA6 
at 7p15.2 is associated with chronic venous disease (36); and 
the TUBA4A/TUBA4B gene at 2q35 is associated with the 
size distribution of platelets (37). The remaining novel genes 
identified in the present study (WNT8B located at chromosome 
10q24.31; HOXC‑AS2 at 12q13.13; ZNF609 at 15q22.31; GDF6 
at 8q22.1; CCDC62 at 12q24.31; MYOM2 at 8p23.3; and the 
RNASE6 gene at 14q11.2) have not previously been reported as 
associated with atherosclerosis-related phenotypes.
It was previously demonstrated that the methylation at 
45 cpG sites differed significantly (P<1.03x10-7) between 
atheromatous plaque lesions and plaque-free intima (19). 
The associations between 23 of these cpG sites [cg02240539 
(P=0.0499), cg04304054 (P=0.0071), cg14521421 (P=0.0033), 
cg14477581 (P=0.0302), cg00909706 (P=3.49x10-6), 
cg00716848 (P=0.0009), cg08466030 (P=8.08x10-6), 
cg22046201 (P=0.0002), cg18516609 (P=0.0188), cg24634746 
(P=8.43x10-6), cg26619894 (P=1.20x10-5), cg03962451 
(P=5.52x10-5), cg12556802 (P=4.90x10-7), cg10586883 
(P=0.0309), cg06208382 (P=1.06x10-6), cg18177814 
(P=0.0013), cg20556639 (P=1.07x10-6), cg09349128 
(P=0.0112), cg26724841 (P=0.0379), cg02196592 (P=0.0235), 
cg16906765 (P=0.0032), cg27647755 (P=1.16x10 -6), 
cg01473038 (P=0.0044)] to atherosclerosis were replicated in 
the present study.
There are several limitations to the present study: i) The 
aortic intima specimens comprised heterogeneous cell types, 
as described previously (19). ii) Although dNA methylation 
status may differ among atherosclerosis, Mönckeberg medial 
sclerosis and arteriolosclerosis, only the aortic intima was 
examined. iii) The association between atherosclerosis 
grade and dNA methylation status was not assessed. iv) The 
effects of hyper- or hypomethylation of cpG sites on the 
expression of genes were not investigated. v) Given the small 
sample size of the current study, the statistical power of the 
genome-wide analysis of dNA methylation was not optimal. 
vi) The molecular mechanisms underlying the effects of dNA 
methylation identified in the present study have not been 
determined definitively. vii) The validation of the results of 
the present study will require replication with other indepen-
dent subject panels.
In conclusion, 16 novel genes that were significantly 
hyper-or hypomethylated in atheromatous plaque lesions 
compared with plaque‑free intima were identified in the present 
study. These results suggest that the methylation status of these 
genes may contribute to the pathogenesis of atherosclerosis. 
The determination of dNA methylation status for the identi-
fied CpG sites may prove informative for the assessment of 
epigenetic risks associated with atherosclerotic cardiovascular 
disease in the Japanese population.
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